The New Technology Add-on Payment (NTAP) Program: What Life Sciences Companies Should Know About Medicare's Time-Limited Program
For biopharmaceutical, medical device and diagnostic manufacturers, navigating market access and reimbursement in the inpatient hospital setting is a challenge in the Medicare program, where most technologies are bundled into an existing payment rate. This bundled payment methodology means that providers often lack incentives to adopt new medical technologies not already reflected in their costs. Since 2001, the Centers for Medicare & Medicaid Services have offered manufacturers of new, groundbreaking technologies the ability to apply for a New Technology Add-on Payment (NTAP) designation for their drug, device or diagnostic that will provide hospitals with extra payments when they use the product for the 2-3 year period after market entry of product. These add-on payments are often critical in a hospital’s decision to adopt new technologies.
Join Foley Hoag and The Moran Company, an HMA Company, on March 29 for a webinar dissecting the upcoming NTAP application process and the frequently asked questions surrounding this time limited program. Our panelists, who have helped dozens of early-stage and mature life sciences companies apply for and receive NTAP designation for their novel medical technologies, will discuss:
- Assessing whether or not your technology qualifies for NTAP
- Why some technologies succeed – and others don’t – during the application process
- The dos and don’ts of engaging with CMS on your application
- Recent rulemaking changes and trends that have emerged in the NTAP program's first two decades